Lumizyme | Patients & Families
Lumizyme ® (alglucosidase alfa) is a medication that replaces a missing or deficient enzyme in people with Pompe disease. If you have Pompe disease, ask your healthcare provider if Lumizyme is an appropriate treatment for you.
Dosing & Administration - Lumizyme
Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during LUMIZYME administration. The recommended dosage of LUMIZYME ® (alglucosidase alfa) is 20 mg per kg of body weight, administered every two weeks as an intravenous infusion. If anaphylaxis or severe ...
Lumizyme | Healthcare Professionals
Explore information for physicians, treatment center staff, and other healthcare professionals about prescribing and administering Lumizyme (alglucosidase alfa). Important Safety Information Prescribing Information
LUMIZYME® (alglucosidase alfa) is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (GAA deficiency). (1) ————————————— DOSAGE AND ADMINISTRATION ————————————— • 20 mg per kg body weight administered every 2 weeks as an intravenous infusion. (2)
LUMIZYME® (alglucosidase alfa) is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase (GAA) deficiency). IMPORTANT SAFETY INFORMATION WARNING: RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, and RISK OF CARDIORESPIRATORY FAILURE
LUMIZYME ® (alglucosidase alfa) is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (GAA deficiency) (1). -----DOSAGE AND ADMINISTRATION----- • 20 mg per kg body weight administered every 2 weeks as an intravenous infusion (2).
Please fill in the following information about the doctor prescribing enzyme replacement therapy for you. Physician First Name: Physician Last Name: